skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: I would like to know if there is any "hanky panky" going on with
SIS and Dejardins. SIS got upgraded by Dejardins from $16 to $17.50 on an earnings miss which made the stock go up over $15. Now Dejardins are the underwriters
of this deal. Also does this type of "you scratch my back and I'll scratch yours"
happen often in the markets?
Read Answer Asked by Herm on April 02, 2019
Q: There's lots of recent news on Onesoft Solutions. New contracts , earnings , and initial coverage report from Beacon Securities with a sizeable upside target price.
The stock has performed well hitting 52 week highs over the last few months and seems like there's traction for growth ...
Would you kindly you give me your overall opinion please ?
Thanks
D.B.
Read Answer Asked by D.B. on April 02, 2019
Q: In February of each year, iShares attributes a significant amount of Non-Cash Re-Investment of Capital Gains for the previous year for holders of CEW. For tax year 2018, it was about $0.533 per unit (roughly 4.3% of unit value). This increases my average cost, so when I sell it in my cash account, my capital gain is reduced (or loss is increased) an equivalent amount. I don't mind this too much in a taxable account.
1. However, If CEW is held in a registered account or a TFSA, am I correct in believing this non-cash reinvestment offers no advantage whatsoever?
2. Why don't these ETFs simply issue a cash distribution? That would benefit owners irrespective of which type of account the units are held in.
Read Answer Asked by EDWARD on April 02, 2019
Q: What are your thoughts on the bought deal private placement of 5M shares? If this was a less common occurrence it would be acceptable but SIS just raised money last year. On both occasions they wait for the share price to get to around $15/$16 and they decide to raise money and drive the share price down. They have set a ceiling on the share price and everytime it gets momentum they send it falling back down to earth. It seems to me that they raise the dividend to drive up the share price only to dilute our shares to get more money. If you need money why raise the dividend 20%, why not keep it the same or slight raise to save money and stop diluting and let the share price go above $16. I've liked mgmt but I'm starting to lose confidence in their decisions around growth. They have just ensured that the share price will fall to $14 tomorrow and stay in that range for months to come. Same as last year. Sorry, frustrated with the recurring dilution. Thanks
Read Answer Asked by Adam on April 02, 2019
Q: Follow-up on my earlier post today relevant to a possible reason for COVALON's 10% jump in stock price: The Zacks report a COV director sent to investors this morning (as an email attachment) is dated: March 18, 2019, and was authored by Brian Marckx, CFA, with Zacks Small Cap Research. While there may be an old Zacks report out there, this one appears to be new.
Read Answer Asked by RANDALL on April 02, 2019
Q: Hi the dividend on this etf shows on iTrade as 3.43%. However the stated dividends of the big five show as being between 3.9-5.2% when I check them individually. Is the difference explained simply by the management fee/mer? Should I sell the etf and just buy say two banks and if so whIch two would you recommend? Thanks, Bill
Read Answer Asked by Bill on April 02, 2019
Q: Jeffrey Mandel (a director on Covalon's Board) sent one of his periodic e-mails directly to COV investors. Today's message included a PDF attachment of a 25pp research document COV apparently commissioned from Zacks Small Cap Research in Chicago. Unsurprisingly, the analysis is glowing, which stated, in part, "We forecast Covalon to generate revenue and EPS of C$53.4M and C$0.13 in 2019 and C$64.5M and C$0.30 in 2020. We value Covalon using a combination of P/S and P/E methodologies. Based on analyst's revenue and EPS estimates of publicly traded companies in focused on wound care and medical supplies, infection control and vascular products, we calculate fair value of Covalon at ~C$11.2/share, or US$8.50 based on current exchange rates."
Read Answer Asked by RANDALL on April 01, 2019
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!